Consensus of European Experts on the Management of Patients with Ischemia with Non-Obstructive Coronary Arteries with Chronic Coronary Syndrome: Possibilities for Use in Outpatient Clinical Practice in Russia

In 2020, a consensus document of the European Society of Cardiology on the management of patients with myocardial ischemia with non-obstructive coronary arteries was released. The main provisions of the new document are aimed at identifying a special group of patients with chronic coronary syndrome and suspected vasospastic or microvascular angina in order to rationalize and personalize the approach to their management. Most patients with established myocardial ischemia do not have obstructive coronary arteries when undergoing coronary angiography. Coronary microvascular dysfunction and epicardial vasospasm, alone or in combination with obstructive coronary artery atherosclerosis, are the causes of myocardial ischemia. In this case, microvascular dysfunction is considered as a significant provoking factor in the pathogenesis of refractory angina pectoris. Diagnosis of such conditions is often difficult, and therefore the correct therapy is not prescribed for such patients. As a consequence, these patients have a poor quality of life, which leads to hospital readmissions, poor cardiovascular outcomes in the short and long term, and a significant burden on health care resources. The article discusses the possibilities of applying new recommendations and consensus in the diagnosis and management of such patients in outpatient clinical practice in Russia. At the initial stages of diagnosis, priority is given to non-invasive research methods; in-depth examination, carried out using invasive methods with a pharmacological testing. Patient management uses a stepwise strategy depending on the specific clinical situation. Calcium channel blockers or beta blockers remain the first line anti-ischemic therapy.

1. Knuuti J., Wijns W., Saraste A. et al. ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2020; 41 (3): 407–477. doi:10.1093/eurheartj/ehz425

2. Drapkina O.M., Samorodskaya I.V., Larina V.N. Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes in Primary Health Care — the Issue of Acceptability for the Russian Federation. Kardiologiia. 2020; 60(4): 130-136. doi:10.18087/cardio.2020.4.n1000. [In Russian]

3. Kunadian V., Chieffo A., Camici P. et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group, European Heart Journal. 2020; 41 (37): 3504–3520, doi:10.1093/eurheartj/ehaa503

4. Pakhtusov N.N., Iusupova A.O., Privalova E.V. et al. Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries. Kardiologiia. 2021; 61(1): 52-58. doi:10.18087/cardio.2021.1.n1423. [In Russian]

5. Sorop O, van den Heuvel M, van Ditzhuijzen NS et al. Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia. Am J Physiol Heart Circ Physiol. 2016; 311: H1339–H1351. doi:10.1152/ajpheart.00458.2015

6. Beltrame JF, Crea F, Kaski JC et al. Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017; 38: 2565–2568. doi:10.1093/eurheartj/ehv351

7. Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011; 124: 1774–1782. doi:10.1161/CIRCULATIONAHA.111.037283

8. Davies A., Fox K., Galassi A. et al. European Heart Journal. 2021; 42 (3): 269–283. doi:10.1093/eurheartj/ehaa820

9. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020; 25(11): 4076. doi:10.15829/29/1560-4071-2020-4076. [In Russian]

10. Mannheimer C., Camici P., Chester M.R. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. European Heart Journal. 2002; 23 (5): 355–370. doi:10.1053/euhj.2001.2706

11. Rakhimov K, Gori T. Non-pharmacological Treatment of Refractory Angina and Microvascular Angina. Biomedicines. 2020; 8(8): 285. doi:10.3390/biomedicines8080285

12. Henry T.D., Satran D., Jolicoeur E.M. Treatment of refractory angina in patients not suitable for revascularization. Nat. Rev. Cardiol. 2013; 11: 78–95. doi:10.1038/nrcardio.2013.200

13. Weisz G., Généreux P., Iñiguez A. et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 6736: 1-10. doi:10.1016/S0140-6736(15)00459-6

14. Calcagno S., Infusino F., Salvi N. et al. The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization. J. Clin. Med. 2020; 9: 2110. doi:10.3390/jcm9072110

15. Samorodskaya I.V. Сontroversial issues in the treatment of coronary artery disease. Complex Issues of Cardiovascular Diseases. 2017; 6(4): 112-120. doi:10.17802/2306-1278-2017-6-4-112-120. [In Russian]